CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 105 enrolled
Drug / intervention
Dose 1 of glycopyrrolate, 2.0% QD +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02129660
NCT02129660Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Blind Vehicle-Controlled Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

Journey Medical Corporation·interventional·Posted May 2, 2014·Updated Sep 17, 2025

In Brief

A Phase 2 clinical trial evaluating Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, and 3 other interventions for Hyperhidrosis. Completed, enrolled 105 participants across 15 sites in 2 countries.

Detailed Summary

The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks followed by a 2-week post-dose period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2, 2014
Enrollment StartApr 1, 2014
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.2 years ago

Interventions

Dose 1 of glycopyrrolate, 2.0% QDdrug

Dose 1 of glycopyrrolate Topical Wipes

Dose 2 of glycopyrrolate, 3.0% QDdrug

Dose 2 of glycopyrrolate Topical Wipes

Dose 1 of glycopyrronium, 2.5% QDdrug

Dose 1 of glycopyrronium Topical Wipes

Dose 2 of glycopyrronium, 3.75% QDdrug

Dose 2 of glycopyrronium Topical Wipes

Vehicleother

Vehicle Topical Wipes